NDA 012911 · Esteve
Metopirone
Metyrapone · Oral · Adrenal Steroid Synthesis Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1961
Dec 4, 1961
Approved uses
1
Original approval plus efficacy supplements
Registered trials
24
3 Phase 3, 4 recruiting
FAERS reports
999
675 serious, 125 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 19, 2026.
Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. ( 1 )
Mechanism: The pharmacological effect of Metopirone is to reduce cortisol and corticosterone production by inhibiting the 11-beta-hydroxylation reaction in the adrenal cortex. Removal of the strong inhibitory feedback mechanism exerted by cortisol results in an increase in adrenocorticotropic hormone (ACTH) production by the pituitary. With continued blockade of the enzymatic steps leading to production of cortisol and corticosterone, there is a marked increase in adrenocortical secretion of their immediate precursors, 11-desoxycortisol and desoxycorticosterone, which are weak suppressors of ACTH...
Therapeutic areas: Kidney and urology · Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 4, 1961 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- METOPIRONE · METYRAPONE 250MG · CAPSULE, ORAL · Prescription
- METOPIRONE · METYRAPONE 250MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Metyrapone" as an intervention, any sponsor and status, largest first.
University of MichiganAcademic, hospital or other
NCT01673087 · 256 participants · Start Oct 2012 · Primary completion Aug 15, 2017
Drug: Metyrapone; Dexamethasone and 2 more · For: Stress
Sites: Ann Arbor, Michigan
- Antiglucocorticoid Augmentation of antiDepressants in DepressionPivotal-lookingCompleted
Jane BarnesAcademic, hospital or other
NCT01375920 · 190 participants · Start Feb 2011 · Primary completion Feb 2013
Drug: Metyrapone; placebo · For: Depression
Sites: Newcastle upon Tyne, United Kingdom; Bradford, United Kingdom; Leeds, United Kingdom · 11 sites in all
- Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)Recruiting
Laikο General Hospital, AthensAcademic, hospital or other
NCT07268222 · 150 participants (planned) · Start Dec 1, 2025 · Primary completion Nov 1, 2026
Drug: Metyrapone 250 mg Oral Tablets; Osilodrostat 1 MG · For: Mild Autonomous Cortisol Secretion (MACS)
Sites: Athens, Greece
Mayo ClinicAcademic, hospital or other
NCT07138274 · 90 participants (planned) · Start Oct 19, 2026 · Primary completion Jun 2031
Drug: Metyrapone 250 mg Oral Tablets; Placebo · For: Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS)
Sites: Rochester, Minnesota
Embera NeuroTherapeutics, Inc.Industry
NCT04501874 · 82 participants · Start Jul 29, 2020 · Primary completion Jul 27, 2022
Drug: EMB-001; EMB-001 Placebo · For: Cocaine Use Disorder
Sites: San Diego, California; Miami, Florida; Philadelphia, Pennsylvania · 4 sites in all
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT00125554 · 63 participants · Start May 1998
Drug: Metyrapone · For: Major Depressive Disorder
Sites: Hamburg, Germany
IRCCS Azienda Ospedaliero-Universitaria di BolognaAcademic, hospital or other
NCT06801249 · 50 participants (planned) · Start Feb 23, 2021 · Primary completion Nov 30, 2024
Drug: Metarapone; Standardized antihypertensive therapy · For: Adrenal Incidentalomas; Cushing Syndrome
Sites: Bologna, Italy; Naples, Italy; Padova, Italy
- Effects of Metyrapone in Patients With Endogenous Cushing's SyndromePivotal-lookingCompleted
HRA PharmaIndustry
NCT02297945 · 50 participants · Start Apr 2015 · Primary completion Nov 2019
Drug: metyrapone · For: Cushing's Syndrome
Sites: Antwerp, Belgium; Brussels, Belgium; Liège, Belgium · 36 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use383
- nausea81
- drug ineffective66
- fatigue53
- vomiting53
- adrenal insufficiency45
- asthenia41
- dizziness41
- death38
- maternal exposure during pregnancy35
- pneumocystis jirovecii pneumonia35
- diarrhoea33
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 3 |
| 2006 | 9 |
| 2007 | 11 |
| 2008 | 3 |
| 2009 | 10 |
| 2010 | 13 |
| 2011 | 16 |
| 2012 | 26 |
| 2013 | 29 |
| 2014 | 11 |
| 2015 | 15 |
| 2016 | 17 |
| 2017 | 34 |
| 2018 | 82 |
| 2019 | 31 |
| 2020 | 57 |
| 2021 | 79 |
| 2022 | 83 |
| 2023 | 80 |
| 2024 | 138 |
| 2025 | 132 |
| 2026 | 114 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Metopirone (Metyrapone)
2024 spending
$1.4M
Beneficiaries
42
132 claims
Per beneficiary
$32,176
$50.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $524,745 |
| 2021 | $866,737 |
| 2022 | $1,085,332 |
| 2023 | $1,090,494 |
| 2024 | $1,351,407 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Subcutaneous pulsatile glucocorticoid replacement therapy.
Russell GM, Durant C, Ataya A, et al. · Clin Endocrinol (Oxf) 2014 · Clinical Trial, Research Support, Non-U.S. Gov't
- Antiglucocorticoid treatments for mood disorders.
Gallagher P, Malik N, Newham J, et al. · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT).
Nieman LK, Boscaro M, Scaroni C, et al. · Eur J Endocrinol 2025 · Multicenter Study, Clinical Trial
- Optimal timing of oral metyrapone intake for the suppression of cold-pressor stress-induced cortisol release.
Drost L, Finke JB, Behrje A, et al. · Psychoneuroendocrinology 2023 · Randomized Controlled Trial
- Suppressing the morning rise in cortisol impairs free recall.
Rimmele U, Meier F, Lange T, et al. · Learn Mem 2010 · Clinical Trial, Research Support, Non-U.S. Gov't
- Mineralocorticoid hypertension in childhood.
New MI, Levine LS · Mayo Clin Proc 1977 · Case Reports, Clinical Trial
Sponsor: Esteve
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.